Company / R&D Expense
C4 Therapeutics, Inc. R&D Expense History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$104.2M
FY2025
5-year range
$94.7M / $117.7M
FY2022-FY2025
Trend
-11.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $118M to $104M over the past 2 years.
Based on SEC 10-K filings.
$104M in FY2025 with a 3-year CAGR of +3.3%.
Declined from $118M to $104M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +3.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +3.3%, indicating consistent growth.
- In FY2025, r&d expense decreased 11.4% year-over-year.
Company context
Key Data Points
- Altman Z-Score -1.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $104.2M | -11.4% |
| FY2024 | $117.7M | +0.0% |
| FY2023 | $117.7M | +24.3% |
| FY2022 | $94.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026